Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Amgen has ended early development of its phase 1 obesity drug, AMG 513. The move comes amid strong financial performance, with the company's Q2 2026 earnings beating expectations and raising its full-year outlook. Amgen's Q2 revenue topped $10.1 billion, marking a 10% increase. The company's decision to discontinue AMG 513 follows a strategic focus on its cholesterol medication, Repatha, which has seen renewed success due to cardiovascular benefits. The decision to drop AMG 513 is part of Amgen's broader strategy to prioritize high-performing assets.

The company's Q2 earnings report underscored its financial strength, with significant revenue growth and an upward revision of its annual sales forecast by $1 billion. Amgen's focus on Repatha, driven by its cardiovascular advantages, has positioned the drug as a key driver of the company's growth. The discontinuation of AMG 513 signals a shift in Amgen's research and development priorities, with an emphasis on therapies that demonstrate clear market potential. Amgen's move impacts the broader pharmaceutical industry, particularly competitors in the obesity treatment market. The pharmaceutical sector is closely watching how MariTide and other companies respond to Amgen's strategic shift.

Investors and industry analysts are evaluating the implications of Amgen's decision on the competitive landscape and the future of obesity treatment development. The next steps for Amgen involve continuing to leverage the success of Repatha and other high-performing drugs. The company's strategic focus on cardiovascular benefits and proven market potential will guide its future research and development efforts. For MariTide and other competitors, the challenge is to accelerate the development of effective obesity treatments and differentiate their offerings in a competitive market.